A multi-centre, two-stage, open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with advanced melanoma

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000910-19

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this clinical trial is to determine the anti-tumor activity of APO866 in patients with advanced cutaneous melanoma.


Critère d'inclusion

  • The medical condition is advanced cutaneous melanoma stage IV or unresectable stage III